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This section deals with the neurologic drugs.  The neurologic drugs are used to treat epilepsy 
and neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease. The 
opioids for pain management are also discussed in this section. 
20. Epilepsy and an introduction to drugs used to treat 
 20.1.1 Introduction to epilepsy 
Epilepsy is a disruption of the normal electrical activity of the brain resulting in seizures.  
Epilepsy affects 1-2% of Australians.  Thus, about 400,000 Australians have epilepsy. 
There are 40 different types of seizures, but they can be grouped together into about 6 main 
groups.  Seizures are associated with changes in sensation, awareness, and behaviour.  Only 
some times are seizures associated with convulsions, muscle spasms or loss of consciousness. 
15% of people with epilepsy have a learning disability. 
About 50% of cases of epilepsy have no known cause.  For the other 50%, the causes of 
epilepsy include head injury, stroke or brain hemorrhage, lack of oxygen to brain for 
prolonged period (birth trauma, cardiac arrest), brain infections, brain tumours, chronic 
alcohol abuse. Epilepsy is not necessarily lifelong, many children or adults outgrow epilepsy 
or have long term remission from epilepsy. 
The pharmacological treatment of epilepsy is quite successful.  Up to 70% of people with 
epilepsy gain full seizure control with treatment. 
Epilepsy can be divided into partial and generalised seizures.  The partial seizures all 
originate from the cerebral cortex.  The cerebral cortex controls a variety of things include 
attention and consciousness.  The partial seizures can be divided into two types; simple, and 
complex (Table 20.1).  Both simple and complex partial seizures can lead to secondary 
generalized tonic-clonic seizures. 
 Table 20.1 Partial seizures (Copyright QUT, Sheila Doggrell) 
Partial seizures begin focally in the cerebral cortex, and with simple partial seizures, the 
manifestations can be diverse depending on the region of the cortex activated.  For instance, 
if the focal point is in the motor cortex representing the left thumb, the epilepsy maybe clonic 
(jerking) of the left thumb.  There is no loss of consciousness with simple partial seizures. 
In contrast, complex partial seizures are associated with a loss of consciousness, and this 
loss of consciousness lasts for 30 seconds to 2 minutes.  Complex partial seizures are also 
associated with purposeful behaviour such as lip smacking or hand wringing. 
Both simple and complex partial seizures can lead to secondary generalised tonic-clonic 
seizures.  These are associated with a loss of consciousness.  In the tonic phase the body 
becomes stiff due to the sustained contraction of muscles, and this is followed by the clonic 
phase when there is jerking of the muscles throughout the body.  These secondary generalised 
tonic-clonic seizures last about 1-2 minutes. 
Generalised seizures involve both hemispheres of the brain from the start (Table 20.2).  In 
absent seizures (petit mal), there is an abrupt onset of impaired consciousness, and this is 
associated with staring and cessation of ongoing activities (rather like a day dream).  Absent 
seizures last 1-2 minutes.  
Myoclonic seizures are brief shock-like contractions of muscle.  Often myoclonic seizures 
are restricted to one extremity (e.g. one leg) but may be more generalised.   
 Table 20.2 Generalised seizures (Copyright QUT, Sheila Doggrell) 
Finally, there are generalised tonic-clonic seizures (grand mal), which have the same 
characteristics as those that can develop from partial seizures, but are not preceded by partial 
seizures. 
The worst type of epilepsy is status epilepticus.  Most partial and generalised seizures 
terminate spontaneously.  When this does not happen, the ongoing tonic-clonic seizures are 
known as status epilepticus.  The definition of what constitutes status epilepticus is 30 
minutes of continuous seizure activity or a series of seizures without return to full 
consciousness between seizures 
Status epilepticus is a very serious condition.  Overall the mortality is about 20% in status 
epileptics, although death is often related to underlying brain injury.  In neonates (newborns) 
status epilepticus may be related to perinatal (period just before and after birth), hypoxia 
insults or metabolic insults.  In the elderly, status epilepticus is usually secondary to ischemic 
insults 
 20.2 Treatment of partial seizures 
The drugs used to treat partial seizures include carbamazepine, phenytoin and valproate.  
These drugs all interact with Na
+
 channels in the nerves in the central nervous system.  
Normally, the Na
+
 channels alternate between the active state, where the channel is open and 
the Na
+ 
flows through the channel to produce nerve activity, and the inactive state (Figure 
20.1).  Carbamazepine, phenytoin and valproate all bind to the inactivated gate of the Na
+
 
channels to prolong the inactivation, which prolongs the quiescent state of the nerve. 
 Figure 20.1 Na
+
 channel (Copyright QUT, Sheila Doggrell) 
Carbamazepine is an important drug for treatment of partial seizures and tonic-clonic 
seizures associated with partial or generalised seizures.  It reduces nerve activity by binding 
to the inactivation gate of the Na
+
 channel and prolonging the time it is inactive.  
Carbamazepine is absorbed slowly and erratically after oral administration. 
Carbamazepine is metabolised to carbamazepine 10,11-epoxide, which is an active 
metabolite.  Carbamazepine also produces autoinduction of its own metabolism by the liver 
enzyme CYP3A4.  Thus, with constant doses of carbamazepine, the plasma concentrations 
will decrease.  Therapeutic drug monitoring of plasma levels of carbamazepine is done on 
a regular basis to ensure that it remains within the therapeutic range. 
Also, by inducing CYP3A4, carbamazepine induces the metabolism off all the drugs 
metabolised by this enzyme, and this can lead to drug interactions.  This includes induction 
of the metabolism of oral contraceptives, and the levels can fall below those needed for 
contraception. 
The most common untoward effects of carbamazepine are drowsiness, vertigo, ataxia 
(unsteady and clumsy motion of the limbs), diplopia (double vision), and blurred vision. 
Phenytoin is also effective in treatment of partial and tonic-clonic seizures.  It also reduces 
nerve activity by binding to the Na
+
 channel, and prolonging the time it is inactive.   
Phenytoin is widely used in absence seizures but not particularly effective against these 
seizures.   
Phenytoin is suitable for oral administration.   Phenytoin is principally metabolised by 
CYP2C9/10.  The metabolism of phenytoin is saturable, which is quite rare, and leads to 
zero order kinetics.  Having zero order kinetics leads to phenytoin having a variable half-life.  
The half-life can range from 6 to 24 hours, as it increases with dose.  Therapeutic drug 
monitoring is often required with phenytoin use. 
Phenytoin induces CYPs including CYP3A4, which means it interacts with all the drugs that 
are metabolised by CYP3A4.  This includes the oral contraceptives. 
Gingival hyperplasia (enlargement of the gums) occurs in about 20% of patients during 
chronic use of phenytoin. 
Valproate, also known as valproic acid, is effective in the treatment of both partial and 
generalised seizures, and is discussed in the next section. 
20.1.3 Treatment of generalised seizures 
In addition to being effective in both partial and generalised seizures, valproate is the 
primary agent used in myoclonic seizures. Like carbamazepine and phenytoin, valproate 
reduces nerve activity by binding to the Na
+
 channel and prolonging the time it is inactive.  
Valproate also has an addition action; it interacts with the T-type Ca
2+
 channels.  Ca
2+
 entry 
via the T-type Ca
2+
 channel underlies some of the currents observed in generalised seizures. 
Valproate inhibits the flow of Ca
2+
 through T-type Ca
2+
 channels. 
Valproate is absorbed rapidly and completely after oral administration.  It has a half-life of 15 
hours, and undergoes metabolism by the liver. 
Most common side effects with valproate are transient gastrointestinal symptoms, including 
anorexia, nausea, and vomiting in about 16% of patients. 
Most barbiturates are active in seizures, but many of the barbiturates cause hypnosis, when 
the subject is in a trance and subject to manipulation.  The only useful barbiturate in epilepsy 
is phenobarbital.  This is because phenobarbital is active in seizures at lower concentrations 
than cause hypnosis.  Phenobarbital is mainly used in myoclonic seizures. 
Phenobarbital is very lipid soluble, and undergoes complete absorption after oral 
administration.  Phenobarbital induces a range of liver metabolising enzymes incluing uridine 
diphosphate-glucuronesyltransferase (UGT) and CYP2C and CYP3A.  Thus, the use of 
phenobarbital will lower the levels of many drugs. 
Sedation is main adverse effect of phenobarbital, and this limits its use.  Phenobarbital 
sometimes causes irritability and hyperactivity in children, and thus is not the primary agent 
for treating epilepsy in children.  Phenobarbital causes agitation and confusion in the elderly, 
and thus it also not the primary agent in the elderly. 
Ethosuximide has as its mechanism of action the ability to inhibit Ca
2+
 currents through T 
channels, which is one of the mechanisms of valproate.  However, unlike valproate, 
ethosuximide has no effect on Na
+
 channels.  This inhibition of Ca
2+
 currents through the T-
type calcium channels includes inhibition of T channels in thalamus, which seem to have a 
major role in absence seizures. 
Ethosuximide is primary agent for the treatment of absence seizures.  Ethosuximide is not 
effective in tonic-clonic seizures.  
The absorption of ethosuximide is complete.  The most common side effects with 
ethosuximide are gastrointestinal (nausea, vomiting, and anorexia) and CNS (drowsiness, 
lethargy, euphoria, dizziness, headache and hiccough/hiccup). 
 20.1.4 Treatment of status epilepticus  
The first line treatment of status epilepticus is the benzodiazepines.  The benzodiazepines are 
used i.v. or rectally.  The benzodiazepines are active after oral administration, but oral 
administration is usually not possible and too slow in status epilepticus.  The benzodiazepines 
most commonly used in the treatment of status epilepticus are lorazepam and diazepam. 
Lorazepam has short onset of action, and a long t1/2 (14 h).  Thus, lorazepam rapidly 
suppresses neuronal activity, and the suppression of neuronal activity with lorazepam lasts 
for long period.  The alternative is diazepam, which is slower to act and the suppression does 
not last so long.  Thus, when diazepam is used in status epilepticus, the status epilepticus may 
break through, and this requires another dose of diazepam to be given. 
The second line treatment for status epilepticus is phenytoin. 
 
20.2. Neurodegenerative disorders; principles of treatment 
The three neurodegenerative disorders considered in this section are Parkinson’s disease, 
Alzheimer’s disease and amytrophic lateral sclerosis (motor neurone disease). 
20.2.1 Introduction to neurodegenerative disorders 
Neurodegeneration is the progressive and irreversible loss of neurones from specific regions 
of the brain. In Parkinson’s disease, the loss of neurones is predominantly the loss of 
dopaminergic neurones from the basal ganglia.  As the basal ganglia have a major role in 
movement, the loss of the dopaminergic neurones gives abnormalities in movement. 
In Alzheimer’s disease, the loss of neurones is from the hippocampal and cortical areas of 
the brain.  As these areas of the brain have a major role in memory and cognitive function, 
the loss of neurones leads to impairment in memory and cognitive function. 
In Amyotrophic Lateral Sclerosis, which is commonly known as motor neuron disease, 
there is a loss of spinal, bulbar and cortical motor neurones.  As motor neurones have a major 
role in movement, loss of these neurones leads to impaired movement.  
 20.2.2 Parkinson’s disease 
  20.2.2.1 Introduction to Parkinson’s disease 
Normal ageing is associated with a loss of dopaminergic neurones.  However, there is a 
greater loss of dopaminergic neurones in Parkinson’s disease, which was first described by 
Parkinson.  Thus, a 70-80% loss of dopaminergic neurones is associated with Parkinson’s 
disease. Pathologically there is loss of dopaminergic neurones in substantia nigra (which is 
part of the basal ganglia).  Also, pathological studies show the appearance of Lewy bodies, 
which are bits of protein dumped in the cell. 
The cause of Parkinson’s disease is usually sporadic.  Sporadic just means irregularly or 
random, and is a term used when it is not know why the disease has occurred.   Parkinson’s 
disease can be genetic.  The antipsychotic agents (which are potent D2 receptor antagonists) 
can cause symptoms similar to Parkinson’s disease called parkinsonism.  
The clinical syndrome that distinguishes Parkinson’s disease consists of 4 parts.  Firstly, there 
is bradykinesia (which is a slowness/poverty of movement).  Secondly, there is muscular 
rigidity, which makes starting a movement difficult.  There may also be resting tremors but 
these usually abate during voluntary movement.  Thus, if a resting tremor occurs during 
sitting, get up and moving around usually gets rid of the tremor.    Lastly, there is 
impairment of balance, with disturbances of gait (movement of limbs) and the subjects with 
Parkinson’s disease lean forward.  Impairment of balance leads to an increased risk of falling. 
The main treatment of Parkinson’s disease is to enhance the dopaminergic system.  This is 
an obvious approach as there is underactivity of the dopaminergic system in Parkinson’s 
disease. 
Normally, the control of movement in the substantia nigra is a balance between the 
cholinergic system and the dopaminergic system.  When the dopaminergic system 
degenerates, the cholinergic system is left unopposed, and predominates.  Thus, an 
overactivity of the cholinergic system is observed.  Consequently, the other approach to 
treating Parkinson’s disease is inhibiting the cholinergic muscarinic neurotransmission. 
  20.2.2.2 Dopaminergic system 
Before we can discuss drugs that enhance the dopaminergic system for use in the treatment of 
Parkinson’s disease, we need to understand the dopaminergic system.  The first step in the 
dopaminergic system is the synthesis of dopamine.  In a dopaminergic neurone, dopamine is 
synthesized from L-dopa in the presence of the enzyme L-aromatic acid decarboxylase 
(Figure 43.1).  
 
Figure 20.1 The dopaminergic system (Copyright QUT, Sheila Doggrell) 
The dopamine (DA) is then stored in a storage vesicle until the nerve is activated.  Once, an 
action potential reaches the nerve ending, there is an increased level of Ca
2+
, and this 
associated with vesicles moving to the cell membrane and dopamine being released.  The 
released dopamine then acts at its receptors on the postjunctional membrane to initiate some 
cell signaling and a final action.   
We can enhance the dopaminergic system at a number of sites in this part of the 
dopaminergic system. For example we can promote the synthesis of dopamine, promote the 
release of dopamine, or stimulate the dopamine receptors. 
 Dopamine is inactivated either by neuronal reuptake (which is similar process as that 
observed with noradrenaline and 5-hydroxytryptamine) or by metabolism.  The metabolism 
involves 3 enzymes; monoamine oxidase (MAO), aldehyde reductase (AD) and catechol-O-
methyl transferase (COMT).  The enzymes act on the dopamine in sequence either firstly 
monoamine oxidase, followed by aldehyde reductase and COMT or COMT followed by 
monoamine oxidase and aldehyde reductase (Fig 43.2).   
 
Figure 20.2 Metabolism of dopamine (Copyright QUT, Sheila Doggrell) 
Although, the intermediate metabolites are different depending on the order of the enzymes 
(metabolites A and B), the final metabolite is the same (metabolite C). 
Importantly, if we inhibit these enzymes, it will lead to a build up of dopamine, which is 
another way to enhance the dopaminergic system.  Thus, drugs that inhibit either monoamine 
oxidase or catechol-O-methyl transferase will increase the levels of dopamine. 
20.2.2.3 Treatment to enhance the dopaminergic system 
Probably, the most obvious way to enhance the dopaminergic system is to give dopamine.  
However, dopamine is not active after oral administration as it is metabolised by monamine 
oxidase and catechol-O-methyl transferase, which are found in the gut.  To avoid intestinal 
metabolism, dopamine can be administered intravenously.  But, after intravenous 
administration, dopamine does not cross the blood brain barrier to have central effects.  Thus, 
we cannot use dopamine in Parkinson’s disease. 
A very important way to enhance the dopaminergic system is to increase the synthesis of 
dopamine.  L-DOPA is the precursor of dopamine.  It is absorbed from the gut on the 
transport system for the aromatic amino acids.  L-DOPA also gains entry into CNS, with 
transport across the blood brain barrier also being mediated by the transporter for the 
aromatic amino acids.  Once in dopaminergic neurones, L-DOPA is converted to dopamine in 
the presence of the enzyme L-aromatic acid decarboxylase. 
There are dopaminergic nerves in the central nervous system and in the peripheral nervous 
system, which means that after the administration of L-dopa, the levels of dopamine are 
boosted in both the central and peripheral nervous system (Figure 43.3).  
In the central nervous system, this achieves are required goal, increased levels of dopamine, 
enhancing the dopaminergic system to overcome the Parkinson’s disease.  However, in the 
peripheral nervous system, the increased levels of dopamine lead to side effects including 
nausea. 
 Figure 20.3 Effect of L-DOPA (Copyright QUT, Sheila Doggrell) 
To overcome this problem, L-DOPA is used with an inhibitor of L-aromatic amino 
decarboxylase that does not cross the blood brain barrier e.g. carbidopa.  Thus, carbidopa 
inhibits the conversion of L-DOPA to dopamine but only in the peripheral nervous system.  
This removes the detrimental effects associated with a build-up of dopamine in the peripheral 
nervous system.  It also means that there are higher levels of L-DOPA in the circulation that 
can be transported to the central nervous system.  In the central nervous system, the L-DOPA 
can still be converted to dopamine to enhance the dopaminergic system to overcome 
Parkinson’s disease.  Thus, with this combination of L-DOPA and carbidopa, we get the 
benefits of L-DOPA in the central nervous system without the peripheral side effects. 
L-DOPA and carbidopa are formulated together into one tablet, which makes it easier for 
the subject to remember to take.  To be effective on an ongoing basis, three or more 
combination tablets are needed a day.  Initially L-DOPA has a dramatic effect in improving 
or removing the signs and symptoms of Parkinson’s disease.  It is like a miracle, the subject 
has apparent full recovery.  Unfortunately, this does not last. 
Parkinson’s disease is a progressive disease, which means there is a progressive loss of 
dopaminergic neurones.  The dopaminergic neurons are needed to convert the L-DOPA to 
dopamine.  Thus, with a decreasing number of dopaminergic neurones present, there is 
decreasing ability of dopaminergic neurones to convert L-DOPA to dopamine.  Thus, the 
miracle does not last.  This progressive loss of dopaminergic neurones contributes to the loss 
of effectiveness of L-DOPA with long term use. 
With long term use of combination of L-DOPA and carbidopa, there is the “wearing off” 
phenomenon.  In the “wearing off” stage, L-DOPA is only effective for 1 to 2 hours, and then 
rigidity and akinesia (slowness/loss of movement) returns.  This is partly due to the 
progressive nature of Parkinson’s disease, but there may be other factors involved.  
Increasing the dose frequency with the L-DOPA can reduced the rigidity and akinesia, but 
often leads to dyskinesia (excessive and involuntary movements).  In addition to nausea, L-
DOPA may induce hallucinations and confusion in the elderly. 
A second approach to enhancing dopaminergic neurotransmission in Parkinson’s disease, is 
to promote the release of endogenous dopamine.  Amantadine increases the release of 
dopamine from the dopaminergic nerves in the striatum 
Amantadine also has antimuscarinic activity and blocks glutamate NMDA receptors and 
these effects may contribute to its benefit in Parkinson’s disease. The benefit of 
antimuscarinic activity in Parkinson’s disease is discussed in the next section.  Blockade of 
glutamate NMDA receptors has been shown to be useful in Alzheimer’s disease. 
Amantadine is not very effective alone.  It is only used alone in the early stages of 
Parkinson’s disease where there are still sufficient stores of endogenous dopamine to allow 
amantadine to release dopamine. 
In late-stage Parkinson’s disease, the disease cannot be controlled by L-DOPA/carbidopa, 
and amantadine can be useful in combination with L-DOPA.  It is especially effective where 
there is dyskinesia with the L-DOPA/carbidopa combination. 
A third approach to enhance dopaminergic transmission is to use drugs that are agonists at 
dopamine D receptor receptors.  Dopamine D1- and D2- receptors are abundant in the 
striatum, and the ones to target in Parkinson’s disease.  Stimulation of these receptors will 
mimic the effect of the missing endogenous dopamine.  There are a number of dopamine 
receptor agonists available including older non-selective agonists: e.g. bromocriptine, and 
some agents that select for one receptor.  Cabergoline is a selective agonist for dopamine D2 
receptors. 
Bromocriptine stimulates vascular D1 receptors to induce vasodilation causing hypotension, 
which is an adverse effect in Parkinson’s disease.  This suggests that agents that are selective 
for dopamine D2-receptor may be better than bromocriptine.  Bromocriptine also causes 
nausea and fatigue. 
Cabergoline is selective for the dopamine D2 receptors, and is generally well tolerated.  It 
has a long elimination half-life, which means that cabergoline can be used once a day. 
Cabergoline can be used alone in early Parkinson’s disease.  Unfortunately, none of the 
presently available dopamine receptor agonists are effective for long when used alone in 
Parkinson’s disease.  Cabergoline can be used in late-stage Parkinson’s disease in 
combination with L-DOPA and carbidopa to overcome the fluctuations with L-DOPA. 
A final approach to enhancing dopaminergic transmission is to reduce the inactivation of 
the endogenous dopamine.  Dopamine is inactivated by either monoamine oxidase or 
catechol-O-methyl-transferase.  
Selegilene is a selective inhibitor of monamine oxidase-B, which is the form of monoamine 
oxidase that breaks down dopamine.  Preventing the metabolism of dopamine, by inhibiting 
monoamine oxidase-B, leads to increased levels of dopamine. 
Unfortunately, the benefit observed with selegilene is modest effect and, consequently, it is 
used primarily in early or mild Parkinson’s disease.  The metabolites of selegilene include 
amphetamine and methamphetamine, which may cause anxiety and insomnia.  
Catechol-O-methyl-transferase (COMT) is involved in the metabolism of dopamine. In the 
periphery, catechol-O-methyl-transferase also metabolises L-DOPA, and this metabolism 
leads to inactivation of the L-DOPA. 
Entacapone is an inhibitor of catechol-O-methyl-transferase.  In the periphery, the ability of 
entacapone to inhibit the inactivation of L-DOPA leads to more L-DOPA being available to 
be transported into the central nervous system.  In the central nervous system, entacapone 
lead to increased levels of dopamine by preventing its metabolism by entacapone.   
The duration of action of entacapone is short; about 2 hours.  Entacapone is not used alone; it 
is usually administered at same time as the L-DOPA/carbidopa combination.  When L-DOPA 
is given alone, up to 99% of it is metabolised in periphery.  The effect of entacapone is 
mainly in the periphery, where inhibiting the metabolism of L-DOPA by catechol-O-
methyltransferase increases the amount of L-DOPA that reaches the central nervous system 
to be converted into dopamine.  Combination tablets of L-DOPA, carbidopa and entacapone 
are available for when the treatment of Parkinson’s disease with the combination of L-DOPA 
and carbidopa is no longer fully effective. 
20.2.2.4 Treatment to inhibit the cholinergic system 
When the dopaminergic system becomes underactive in Parkinson’s disease, it leaves the 
cholinergic system unopposed, and this produces an apparently overactivity cholinergic 
system.  Thus, another approach to the treatment of Parkinson’s disease is to inhibit the 
cholinergic system. 
Four, possibly 5, of the muscarinic subtypes are present in the striatum.  However, inhibition 
of muscarinic receptors only has a modest benefit in Parkinson’s disease.  Thus, the 
antimuscarinic agents are not used alone in Parkinson’s disease, but rather can be used as an 
adjunct to L-DOPA based therapy.  Thus, when the L-DOPA/carbidopa effect is waring off, 
antimuscarinic agent may be added. 
To be effective in the treatment of Parkinson’s disease, it is necessary to have an 
antimuscarinic agent that crosses the blood brain barrier.  Benzotropine crosses the blood 
brain barrier and is used in the treatment of Parkinson’s disease.  Some of the adverse 
effects observed with benzotropine are due to central anti-muscarinic activity e.g. sedation 
and mental confusion.  Benzotropine will also be found in the periphery after oral 
administration.  Consequently, adverse effects are observed to benzotropine which are due to 
peripheral anti-muscarinic activity e.g. constipation, urinary retention, and blurred vision 
through cycloplegia. 
 
20.2.3 Dementia/Alzheimer’s disease 
Alzheimer’s disease (AD) is not the only dementia, although it is the most common.  
Vascular dementia follows stroke, where following the blockage of cerebral blood vessels, 
the lack of oxygen and nutrients initiates the death of neurones.  Vascular dementia can take 
different forms, depending on where the blood vessel is that was blocked.  Dementia with 
Lewy bodies (abnormal spherical structures inside nerve cells) often occurs in subjects with 
long term Parkinson’s disease.  Mixed dementia is when Alzheimer’s disease and vascular 
dementia occur in the same person. 
20.2.3.1 Introduction to Alzheimer’s disease 
The prevalence of Alzheimer’s disease is 10% in those over 65 years of age.  Alzheimer’s 
disease equally affects men and women.  In Alzheimer’s disease there is atrophy of cerebral 
cortex; that is a loss of cortical and subcortical neurones.  Also, in Alzheimer’s disease there 
is the accumulation of senile plaques containing the protein β-amyloid (which is a 
neurotoxin) and of neurofibrillary tangles. 
In Alzheimer’s disease, there is a striking and disproportional loss of the neurotransmitter 
acetylcholine (Ach), but this is not the only loss in Alzheimer’s disease.  There is also a loss 
of tryptaminergic (5-HT), glutaminergic (glutamate) and neuropeptide neurotransmission. 
Alzheimer’s disease is well known for giving an impairment of cognitive abilities.  This 
impairment is gradual in onset but relentless (keeps getting worse).  There is impairment of 
short-term memory – progresses from decreased ability to calculate, decreased visuospatial 
skills, decreased ability to use common objects/tools,  to decreased arousal/alertness.   Death 
occurs, 6-12 years after onset, usually due to complications of the immobility associated with 
the latter stages of the disease. 
20.2.3.2 Treatment of Alzheimer’s disease 
There are presently no good treatments for Alzheimer’s disease (AD).  The most commonly 
used treatment is to enhance the cholinergic system.  Another approach to the treatment of 
Alzheimer’s is to inhibit glutamate receptors. 
The cholinergic system is enhanced in Alzheimer’s disease by inhibiting 
acetylcholinesterase, the enzyme that breaks down acetylcholine.  Inhibition of 
acetylcholinesterase leads to increased concentrations of acetylcholine in the synapses in the 
brain.  However, improvements with anticholinesterases in Alzheimer’s disease are marginal.  
Overall the anticholinesterases cause a decrease in rate of decline in subjects with 
Alzheimer’s disease (Figure 43.4). 
 
Figure 20.4 Effect of anticholinesterase in AD (Copyright QUT, Sheila Doggrell) 
Most of the benefit of anticholinesterase in Alzheimer’s disease is seen in mild-to-moderate 
disease (i.e. the early stages of Alzheimer’s disease). 
To be useful in the treatment of Alzheimer’s disease, an anticholinesterase agent must cross 
the blood brain barrier and have a prominent effect in the central nervous system.  
Doneprezil is an anticholinesterase that acts predominantly in the central nervous system, but 
will also have effects in the peripheral nervous system.  The side effects of doneprezil are 
due to its widespread ability to increase the levels of acetylcholine in synapses, and they 
include nausea, diarrhea, vomiting and insomnia. 
The other approach to treating Alzheimer’s disease is to use glutamate NMDA receptor 
antagonists.  When glutaminergic neurones breakdown, glutamate is released, and the levels 
of glutamate are very high leading to excessive stimulation of glutamate receptors.  It has 
been shown that the excessive stimulation of the glutamate NMDA receptors may have a role 
in the pathology of Alzheimer’s disease.   
The drugs initially developed as NMDA receptor antagonists had too many adverse effects to 
be used in the clinic.  However, an old drug that had been used for others purpose, which is 
an antagonist at glutamate NMDA receptors is used.  The old drug is memantine.  
Memantine is a non-competitive and relatively weak antagonist at NMDA receptors.  It has 
been shown to slow the decline in moderate-to-severe Alzheimer’s disease.  Thus, memantine 
is effective in a later stage of Alzheimer’s disease than doneprezil. 
 
20.2.4 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis is also known as motor neurone disease. 
20.2.4.1 Introduction 
Amyotrophic lateral sclerosis occurs in 5 out of 100,000 people, and occurs more common in 
men than women. About 10% of cases are familial (genetically linked), and 90% of cases are 
sporadic (unknown cause).  Motor neurone disease usually presents between the ages 50-70 
years. 
Amyotrophic lateral sclerosis or motor neurone disease is a disorder of the motor neurones of 
the ventral horn of the spinal cord and the cortical neurones that provide the afferent input to 
that area.  There is a selective loss of the spinal and brainstem motor neurones.   
The symptoms of motor neuron disease are muscle wasting, muscle fasciculation, spasticity 
or stiffness in arms and legs, and overactive tendon reflexes.  Motor neurone disease is 
progressive and fatal.  Death usually occurs after 2-3 years with respiratory compromise and 
pneumonia the most common reasons for death.  
20.2.4.2Treatment  
Riluzole prolongs survival in motor neurone disease by about 60 days, and is considered to 
be disease-modifying.  The mechanism of action of riluzole is unclear.  Riluzole probably 
reduces the neurotoxicity of glutamate by inhibiting the release of glutamate, and blocking 
some of the glutamate receptors.  Riluzole is generally well tolerated.  One precaution when 
using riluzole is to motor liver enzymes (e.g. aminotransferases) as, very occasionally, there 
is toxicity to the liver with riluzole. 
Baclofen, a GABAB receptor antagonist is used for the symptomatic relief of the spasticity 
associated with motor neurone disease. 
 
  
20.3. Pain and opioid analgesics 
20.3.1 Introduction to pain and analgesia 
There are two main types of pain; nociceptive and neuropathic.  Nociceptive pain is due to 
the activation of pain fibres.  The pain fibres may be somatic with the pain coming from the 
skin and muscle or visceral with the pain coming from organs such as the liver. 
Neuropathic pain is due to nerve injury and the nerve injury can be due to disease or 
surgical section occurring in the pain pathway.  Peripheral neuropathic pain is associated 
with disease such as post-herpetic neuralgia (after shingles, herpes zoster can damage 
nerves), or diabetic neuropathy, where the high levels of sugars lead to damage to the nerves.  
Phantom limb pain, where a limb has been removed but the subject is still aware of pain from 
the limb is another example of peripheral neuropathic pain. Central neuropathic pain is 
associated with spinal cord injury, where the nerve is injured by trauma, and stroke, where 
the nerve is damaged as a result of the ischaemia (lack of oxygen/nutrients). 
Pain can be either acute or chronic.  Acute pain is usually rapid onset, short duration, and the 
cause is often known (e.g. disease, trauma).  Pain can also be chronic, which is defined as 
lasting for more than 3 months.  Chronic pain can be cancer or non-cancer pain. 
Opioids are not the only drugs used to relied pain (analgesia).  The analgesic used depends on 
the intensity of the pain (Figure 20.5). 
 
Figure 20.5 Treatment of pain (Copyright QUT, Sheila Doggrell) 
When the intensity of pain is low, the treatment is the non-opioid analgesics, predominantly 
the COX inhibitors such as aspirin, paracetamol, and naproxen.  When the pain is greater 
and cannot be managed with the non-opioids, the weak opioids are used e.g. codeine.  
Codeine is partly metabolised to morphine, and acts as a weak opioid.  The weak opioids are 
often used with the COX inhibitors.  If the pain intensity is such that it cannot be managed 
with the weak opioids, strong opioids such as morphine are used in the treatment.  Most pain 
can be managed be morphine, but if very intense pain cannot be managed with oral, or 
subcutaneous/ intramuscular/intravenous morphine, the morphine or other agents may be 
applied intraspinally.  In addition to morphine, the local anaesthetics are used intraspinally in 
intense pain.   
20.3.2 Introduction to opioids 
Opium is the juice of the opium poppy.  Opiates (also known as opioids) are the drugs 
derived from opium, and these are morphine and codeine.   
The effects of taking opioids, and even that they were receptor-mediated, was known before 
the endogenous opioid system was discovered.  Thus, we knew that the opioids were 
effective at promoting pain relief, and that the effect was mediated by a receptor in the body 
for opioids, before we knew what the receptors were doing in the body.  
There are opioid receptors in the body to mediate the effects of the endogenous opioid 
peptides.  The endogenous opioids include enkephalins, endorphins, and dynorphins.  There 
are at least three types of opioid receptor for these endogenous opioids, and they are known 
as μ (mu), δ (delta), and κ (kappa) receptors. 
The analgesic effect of opioids is mediate by the μ receptor.  The μ receptors are found in the 
spine (spinal) and in the brain (supraspinal, above the brain).  
The opioids discussed in this chapter include morphine and fentanyl.  Both morphine and 
fentanyl are full agonists at μ receptors.  Codeine is a weak opioid.  Codeine itself is not an 
opioid, but 10% of it is metabolised to morphine, which is an opioid.  Buprenorphine is a 
partial agonist at μ receptor, which means it gives a lesser maximal response that morphine 
does at μ receptors.  Tramadol is a weak agonist at μ receptor.  Tramadol also inhibits the 
SERT (transport of 5-HT) and the NET (transport of noradrenaline) to increase the levels of 
5-HT and noradrenaline in the brain. 
20.3.3 Tolerance and physical dependence 
Tolerance and physical dependence develops to the opioids.  Tolerance is a decrease in 
effectiveness with repeated use of the same dose of a drug.  Tolerance occurs to most of the 
effects of the opioids.  Thus, it is necessary to increase dose to maintain the same effect.  The 
possible mechanisms for the development of tolerance include receptor internalization with 
chronic exposure to the opioids, so that they are no longer activated by the opioid.  An 
alternative mechanism for the tolerance is an altered responsiveness of the cell signaling with 
chronic exposure to the opioids to give a diminished response. 
Physical dependence is a set of changes in the body with chronic exposure leading to a 
withdrawal syndrome when the drug is stopped due to changed homeostasis.  Physical 
dependence can develop to opioids, for example, when morphine is in chronic use for the 
pain of cancer.  Physical dependence is not drug addiction or abuse.  Drug addiction is due to 
psychological dependence and pleasurable effects causing reinforcement of drug use.  
Subjects with pain do not usually have these and are not drug addicts.  Opioids can be 
discontinued in physically dependent patients (subjects who have had chronic pain) without 
subjecting them to withdrawal. Associated with decreasing the dose of opioid by 10 to 20% 
every other day, and eventually stopping the opioid, there is no withdrawal syndrome. 
20.3.4 Effects of opioids 
The reason why opioids are used extensive clinically is that they are potent analgesics. The 
opioids inhibit the ascending nociceptive information from the spinal cord, so that no pain is 
felt.  The opioids also activate descending pain control circuits to reduce pain. 
They reason why opioids are abused extensively is that they cause mood alteration.  
Opioids, especially heroin, cause a feeling of euphoria and tranquillity. 
The diagnosis of opioid abuse is helped by the fact that they cause miosis.  Miosis with the 
opioids is due to constriction of the pupil by an excitatory action on the parasympathetic 
nerve innervating the pupil that leads to pinpoint pupils.  This is termed pathognomonic, 
which means it is a unique pathological characteristic of opioid use.  Some tolerance to the 
pinpoint pupils does develop, but this is not as great as other tolerances to opioids, and opioid 
abusers continue to have constricted pupils. 
Opioids in high doses can cause nausea and vomiting.  This nausea and vomiting is caused 
by direct stimulation of the chemoreceptor trigger zone, which is the centre in the brain that 
controls nausea and vomiting. 
Opioids in high doses have effects on respiration.  The opioids depress respiration by a 
direct effect on the brainstem respiratory centres.  Respiratory depression is the main cause of 
death with the opioids.  For instance, subjects that abuse the opioids become tolerant, and use 
high doses.  When the supply of heroin dries up, this tolerance reverses.  If the addict then 
takes the high dose of heroin that they were using previously, there will be excessive 
respiratory depression and, possibly, death. 
Opioids depress cough.  Opioids have a direct effect on the cough centre in the medulla, 
which leads to a depression of cough. 
Opioids also have effects where they cause peripheral vasodilation and inhibition of the 
baroreceptor reflex.  These effects lead to a decrease in blood pressure. 
Opioids have effects on the gastrointestinal tract.  They inhibit secretions, and they also 
decrease transit time, which leads to constipation.  This is a major problem with both the 
clinical use and abuse of opioids.  Tolerance does not develop to this effect of the opioids. 
Opioids also have effects on the urinary bladder.  They inhibit the urinary voiding reflex, 
which leads to urinary retention. 
 20.3.5 Agonists at opioid µ receptors 
This section considers the individual drugs that act as agonists at the opioid µ receptors.  One 
of the main agents used clinically is morphine. 
20.3.5.1 Morphine 
Morphine is readily absorbed from the gastrointestinal tract, the rectal mucosa, the skin, and 
muscle.  Morphine is available in oral, suppository preparations (rectal), subcutaneous, and 
intramuscular preparations.  It is used intravenously for fast action.  Morphine can be 
introduced into the epidural or intrathecal space, from which it penetrates into spinal cord.  
As the spinal cord is the site of action of morphine, achieving high concentrations in the 
spinal cords achieves high levels of pain relief. 
Morphine undergoes considerable first pass metabolism, such that bioavailability is only 
about 25% after oral administration.  Thus, high doses of morphine have to be give orally, to 
achieve reasonably plasma levels.  A broad range of steady-state plasma concentrations of 
morphine (16 to 364 ng/ml) is associated with analgesia.  
As morphine is metabolised by the liver, in hepatic dysfunction, it may be necessary to 
decrease the dose of morphine, as bioavailability may be increased. Morphine is metabolised 
to morphine-6-glucuronide and morphine-3-glucuronide.  Morphine-6-glucuronide is an 
active metabolite.  Morphine-6-glucuronide is actually more potent than morphine as an 
agonist at µ-receptors, and therefore, in causing pain relief. The half-life of morphine is 2 
hours, whereas morphine-6-glucuronide has a longer half life, thus, the pain relieving effect 
of morphine is prolonged, and the prolongation is due to the morphine-6-glucuronide. 
Morphine-6-glucuronide is excreted by the kidney.  In kidney disease, it may be necessary to 
decrease the dose of morphine, as there may be accumulation of the morphine-6-glucuronide.  
Accumulation of morphine-6-glucorinide may lead to excessive respiratory depression. 
Because of the respiratory depression, morphine should be used with caution in people with 
compromised respiratory function.  For instance, morphine should be used with caution in 
subjects with emphysema. 
Most of the unwanted effects of morphine are part of, or extensions of, stimulating the µ-
receptors, and include excessive respiratory depression, nausea and vomiting, and 
constipation.  Morphine also causes hypotension, due to its ability to cause peripheral 
vasodilation and inhibiting the baroreceptor reflex.  Also, morphine can cause urinary 
retention.  
In high doses, the euphoria with morphine goes, and is replaced by dizziness, mental 
clouding, and dysphoria.  Dysphoria is a feeling of anxiety, depression, and unease.   
Morphine can also cause pruritis (itchy skin).  
20.3.5.2Codeine 
Codeine itself has low affinity for opioid receptors.  However, 10% of codeine is 
metabolised by the liver enzyme CYP2D6 to morphine, and morphine is responsible for the 
analgesic effect with morphine. 
Polymorphisms in CYP2D6 lead to an inability to make morphine from codeine, and these 
polymorphisms affect 10% of Caucasians.  This 10% of Caucasians have an inadequate 
analgesia response to codeine. 
Codeine is considered to be a weak opioid, and is used on the second step in the treatment of 
pain (Figure 20.6).  It is used in mild-to-moderate pain.  Codeine is sometimes used in 
combination with the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) e.g. paracetamol. 
Another use of codeine is as an anti-tussive (in cough).  The mechanism underlying this 
beneficial effect of codeine in cough is unknown but is unlikely to involve μ-receptors, as it 
is not a property observed with the other μ-receptor agonists.  
20.3.5.3 Fentanyl 
Fentanyl is the opioid commonly preferred by anaesthesiologists as an adjunct to general 
anaesthesia.  It is preferred because it is easy to manage.  It has a short time to peak 
analgesic effect (about 5 minutes) and rapid termination of effect after intravenous bolus 
doses are stopped.   
Decreases in blood pressure can be a problem with the opioids.  Fentanyl is preferred by 
anaesthesiologists as it has relative cardiovascular stability i.e. does not have major effects 
on blood pressure. 
Fentanyl is administered epidurally and intrathecally for acute postoperative and chronic pain 
management. 
Fentanyl is highly lipid soluble and rapidly cross blood brain barrier.  Fentanyl, like all highly 
lipid soluble drugs, is initially distributed to the highly perfused tissues.  Then, it is 
redistributed from highly perfused tissues to those with lower perfusion (muscle and fat). 
Fentanyl undergoes hepatic metabolism and kidney excretion.  There are no active (toxic) 
metabolites of fentanyl, and consequently, it can be used in renal impairment, whereas other 
opioids (e.g. morphine) are difficult to use in renal impairment. 
20.3.3.5 Buprenorphine 
Morphine stimulates opioid -receptors to induce analgesia.  Another effect mediated by 
opioid -receptors is respiratory depression.  Respiratory depression is a common side effect 
associated with full agonists at opioid -receptors (e.g. morphine) 
Buprenorphine is a partial agonist at opioid -receptors.  Buprenorphine causes analgesia 
but is unlikely to cause excessive respiratory depression.  
Buprenorphine is relatively well absorbed from most routes.  It can be used sublingually for 
rapid relief of pain in post-operative patients.  Buprenorphine is a slowly dissociating 
agonist, which means it sticks to the receptors.  When the buprenorphine is associated with 
the receptors, it is not in the plasma.  Thus, the plasma levels of buprenorphine can be very 
low but buprenorphine is still having an effect, as it is bound to receptors. 
Buprenorphine is used as an analgesic.  Buprenorphine is also used in opioid addiction, where 
it can be used to stabilise the addict prior to a gradual reduction of dose. 
20.3.3.6 Tramadol 
Tramadol is a weak agonist at μ-receptors.  Tramadol also inhibits the serotonin transporter 
(SERT) and noradrenaline transporter (NET) to increase the levels of 5-HT and 
noradrenaline, respectively, in the brain.  It has been postulated that this 5-HT and 
noradrenaline may contribute to analgesic effect of tramadol. 
The demethylated metabolite of tramadol is more potent than tramadol at stimulating μ-
receptors.  Thus, the metabolite will contribute to the analgesic effect of tramadol. 
Tramadol is used orally (where it has a 68% bioavailability) or intramuscularly (100% 
bioavailability).  It is used in the treatment of mild-to-moderate pain, which is step 2 of 
Figure 20.1.  Tramadol is not as effective as morphine for the treatment of severe pain (step 
3).  
20.4 Toxicity to opioids 
A number of causes can underlie the toxicity to opioid.  The causes include accidental 
clinical overdosage, accidental overdosage in addicts, and suicide attempts. 
Opioid poisoning is easily recognise by the triad (combination) of coma, pinpoint pupils, 
and depressed respiration.  Treatment of poisoning is always treating the subject first, and 
then treating the poison.  Thus, the initial treatment is artificial ventilation to overcome the 
depressed respiration. 
Then the poison opioid is treated with naloxone, a non-selective opioid antagonist.  In 
subjects who are physically dependent, naloxone can precipitate the opioid withdrawal 
syndrome.  To prevent, this there is the slow administration of low dose of naloxone, with 
constant monitoring of respiration. 
